Objective: To explore the expression, functional enrichment and signal pathway of CCNB1 in cervical cancer and its relationship with patients’ prognosis. Methods: The expression of CCNB1 in cervical cancer and its adjacent tissues was analyzed with bioinformatics data analysis. The biological function and signal pathway of CCNB1 were enriched, and the protein interaction network of CCNB1 expression was constructed in the STRING database. The relationship between CCNB1 expression and overall survival (OS) and disease free survival (DFS) was analyzed using Kaplan Meier database. Results: The expression level of CCNB1 in cervical cancer tissues was significantly higher than that in adjacent tissues (P＜0.05). The biological processes, cell components and molecular functions of CCNB1 are mainly enriched in cell division and cell cycle, and the activity of serine / threonine kinase in cytoplasm and cyclin dependent protein. KEGG related signaling pathways mainly include cell cycle, progesterone mediated oocyte maturation and oocyte meiosis. The protein-protein interaction relationship of CCNB1 and its interaction protein network was 196, the average aggregation index was 0.944, the interaction of protein-protein interaction network was significant (P＜0.005). The OS (HR=1.62, 95 % CI: 1.10-2.62, P＜0.05) and DFS (HR=3.53, 95 % CI:1.62-7.69, P＜0.05) of patients with high expression of CCNB1 were significantly lower than those with low expression of CCNB1 . CCNB1 expression was not correlated with B lymphocytes (r=-0.099, P＞0.05), CD8+T cells (r=-0.036, P＞0.05), CD4+T cells (r=0.065, P＞0.05), macrophages (r=-0.79, P＞0.05), neutrophils (r=0.1, P＞0.05) and dendritic cell infiltration (r=0.8, P＞0.05). Conclusion: CCNB1 is highly expressed in cervical cancer, and is involved in the occurrence and development of cervical cancer. Its high expression is related to poor prognosis of patients, which may be a new target for targeted therapy of cervical cancer.
JI Xia
,
GUO Hairong
,
WANG Ning
,
GAO Jie
,
QIN Shuli
,
DU Haiyan
. Biological function of CCNB1 in cervical cancer and its relationship with prognosis: a bioinformatics analysis[J]. Journal of Baotou Medical College, 2023
, 39(7)
: 29
-33
.
DOI: 10.16833/j.cnki.jbmc.2023.07.006
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview[J].Int J Cancer, 2021, 149(4): 778-789.
[3] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J].CA Cancer J Clin, 2021, 71(1): 7-33.
[4] Liu AW, Zeng SX, Lu X, et al. Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor prognosis in bladder cancer[J].Int J Biol Macromol, 2019, 123: 322-334.
[5] 李莉, 熊国平, 颜琳, 等. CCNB1在卵巢癌中的表达及意义[J].现代妇产科进展, 2016, 25(11): 818-820, 824.
[6] 杨生辉, 黄琰菁, 邱纯, 等. 基于数据库探讨细胞周期蛋白B1(CCNB1)表达对胃癌预后的影响[J].中国数字医学, 2020, 15(1): 37-40.
[7] Hoffmann R, Valencia A. A gene network for navigating the literature[J].Nat Genet, 2004, 36(7): 664.
[8] Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C[J].Curr Opin Cell Biol, 2000, 12(6): 658-665.
[9] Porter LA, Donoghue DJ. Cyclin B1 and CDK1: nuclear localization and upstream regulators[J].Prog Cell Cycle Res, 2003, 5: 335-347.
[10] Xie BW, Wang SY, Jiang N, et al. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance[J].Cancer Lett, 2019, 443: 56-66.
[11] Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer[J].Cancer Res, 2006, 66(1): 6-9.
[12] Fang YF, Yu H, Liang X, et al. Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer[J].Cancer Biol Ther, 2014, 15(9): 1268-1279.
[13] Ding K, Li WQ, Zou ZQ, et al. CCNB1 is a prognostic biomarker for ER+ breast cancer[J].Med Hypotheses, 2014, 83(3): 359-364.
[14] Fang L, Du WW, Lyu JJ, et al. Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1[J].Cell Death Differ, 2018, 25(12): 2195-2208.
